• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌的预后与充分/恰当治疗之间的关系

Prostate cancer between prognosis and adequate/proper therapy.

作者信息

Grozescu T, Popa F

机构信息

"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

出版信息

J Med Life. 2017 Jan-Mar;10(1):5-12.

PMID:28255369
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5304372/
Abstract

Knowing the indolent, non-invasive nature of most types of prostate cancer, as well as the simple fact that the disease seems more likely to be associated with age rather than with other factors (50% of men at the age of 50 and 80% at the age of 80 have it [], with or without presenting any symptom), the big challenge of this clinical entity was to determine severity indicators (so far insufficient) to guide the physician towards an adequate attitude in the clinical setting. The risk of over-diagnosing and over-treating many prostate cancer cases (indicated by all the major European and American studies) is real and poses many question marks. The present paper was meant to deliver new research data and to reset the clinical approach in prostate cancer cases.

摘要

鉴于大多数类型的前列腺癌具有惰性、非侵袭性的特点,以及该病似乎更可能与年龄相关而非其他因素这一简单事实(50%的50岁男性和80%的80岁男性患有前列腺癌,无论有无症状),这个临床实体面临的重大挑战是确定严重程度指标(目前尚不充分),以指导医生在临床环境中采取适当的应对措施。过度诊断和过度治疗许多前列腺癌病例的风险(所有主要欧美研究均表明)是切实存在的,并且带来了许多疑问。本文旨在提供新的研究数据,并重新调整前列腺癌病例的临床治疗方法。 []内内容原文未给出,无法准确翻译

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c397/5304372/ca88ea0cf32a/JMedLife-10-5-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c397/5304372/ca88ea0cf32a/JMedLife-10-5-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c397/5304372/ca88ea0cf32a/JMedLife-10-5-g001.jpg

相似文献

1
Prostate cancer between prognosis and adequate/proper therapy.前列腺癌的预后与充分/恰当治疗之间的关系
J Med Life. 2017 Jan-Mar;10(1):5-12.
2
African-American Prostate Cancer Disparities.非裔美国人前列腺癌差异
Curr Urol Rep. 2017 Aug 14;18(10):81. doi: 10.1007/s11934-017-0724-5.
3
Predictive models in diagnosing indolent cancer.惰性癌症诊断中的预测模型
Cancer. 2009 Jul 1;115(13 Suppl):3100-6. doi: 10.1002/cncr.24347.
4
Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.前列腺癌发病率和死亡率的预防:一级预防与早期检测
Med Clin North Am. 2017 Jul;101(4):787-806. doi: 10.1016/j.mcna.2017.03.009.
5
Epidemiology, diagnosis and treatment of prostate cancer.前列腺癌的流行病学、诊断与治疗
Radiol Technol. 1996 Sep-Oct;68(1):39-64; quiz 65-8.
6
Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection.评估前列腺癌早期检测项目中高危男性的早发性前列腺癌遗传标志物的临床作用。
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):53-60. doi: 10.1158/1055-9965.EPI-11-0727. Epub 2011 Dec 5.
7
Molecular Biomarkers in the Clinical Management of Prostate Cancer.**标题**: 前列腺癌临床管理中的分子生物标志物 **正文**: 前列腺癌是男性最常见的恶性肿瘤之一,其临床管理涉及多个方面,包括诊断、分期、治疗选择和预后评估。近年来,随着分子生物学技术的不断发展,越来越多的分子生物标志物被发现与前列腺癌的发生、发展和转移密切相关,为前列腺癌的临床管理提供了新的思路和策略。本文就前列腺癌临床管理中常用的分子生物标志物及其应用价值进行综述。
Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a030601. doi: 10.1101/cshperspect.a030601.
8
The contemporary concept of significant versus insignificant prostate cancer.当代有意义与无意义前列腺癌的概念。
Eur Urol. 2011 Aug;60(2):291-303. doi: 10.1016/j.eururo.2011.05.006. Epub 2011 May 17.
9
[Not Available].[无可用内容]
Praxis (Bern 1994). 2016 Aug;105(16):971-7. doi: 10.1024/1661-8157/a002437.
10
How AI Is Optimizing the Detection and Management of Prostate Cancer.人工智能如何优化前列腺癌的检测与管理。
IEEE Pulse. 2018 Sep-Oct;9(5):19. doi: 10.1109/MPUL.2018.2866354.

引用本文的文献

1
Diagnostic value of CD138 and GATA3 in benign prostatic hyperplasia and prostate cancer.CD138和GATA3在良性前列腺增生和前列腺癌中的诊断价值。
Discov Oncol. 2025 Jun 23;16(1):1183. doi: 10.1007/s12672-025-02984-4.
2
Applications and Outcomes of Telehealth and Integrated Care in Men's Health Urology.远程医疗与综合护理在男性健康泌尿学中的应用与成果
J Med Internet Res. 2025 Jun 18;27:e69095. doi: 10.2196/69095.
3
Lived Experience of Men with Prostate Cancer in Ireland: A Qualitative Descriptive Study.爱尔兰前列腺癌男性患者的生活经历:一项质性描述性研究。

本文引用的文献

1
The Proteome of Primary Prostate Cancer.原发性前列腺癌的蛋白质组。
Eur Urol. 2016 May;69(5):942-52. doi: 10.1016/j.eururo.2015.10.053. Epub 2015 Dec 2.
2
Polymorphism of the SRD5A2 gene and the risk of prostate cancer.SRD5A2基因多态性与前列腺癌风险
Mol Med Rep. 2014 Dec;10(6):3151-6. doi: 10.3892/mmr.2014.2621. Epub 2014 Oct 10.
3
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.随机前列腺癌、肺癌、结直肠癌和卵巢癌筛查试验中的前列腺癌筛查:13 年随访后的死亡率结果。
Healthcare (Basel). 2025 May 2;13(9):1049. doi: 10.3390/healthcare13091049.
4
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries.肢端肥大症患者的癌症筛查:呼吁采用个性化方法并建立国际登记系统。
Rev Endocr Metab Disord. 2025 Mar 15. doi: 10.1007/s11154-025-09957-6.
5
Application of mobile internet management in the continuing care of patients after radical prostatectomy.移动互联网管理在前列腺癌根治术后患者延续性护理中的应用
Sci Rep. 2024 Dec 28;14(1):31520. doi: 10.1038/s41598-024-83303-9.
6
Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study.结合组织生物标志物与多参数磁共振成像诊断具有临床意义的前列腺癌。PICTURE研究中21种生物标志物的分析。
Prostate Cancer Prostatic Dis. 2024 Nov 22. doi: 10.1038/s41391-024-00920-1.
7
Cribriform Pattern Is a Predictive Factor of PSA Recurrence in Patients Receiving Radiotherapy After Prostatectomy.筛状模式是前列腺切除术后接受放疗患者前列腺特异性抗原复发的预测因素。
Cancer Diagn Progn. 2024 Nov 3;4(6):715-721. doi: 10.21873/cdp.10386. eCollection 2024 Nov-Dec.
8
Advances in research on the relationship between the LMNA gene and human diseases (Review).LMNA 基因与人类疾病关系的研究进展(综述)。
Mol Med Rep. 2024 Dec;30(6). doi: 10.3892/mmr.2024.13358. Epub 2024 Oct 18.
9
Precision molecular insights for prostate cancer prognosis: tumor immune microenvironment and cell death analysis of senescence-related genes by machine learning and single-cell analysis.前列腺癌预后的精准分子见解:通过机器学习和单细胞分析对衰老相关基因进行肿瘤免疫微环境和细胞死亡分析
Discov Oncol. 2024 Sep 27;15(1):487. doi: 10.1007/s12672-024-01277-6.
10
Novel Mutations in Gene in Prostate Cancer Patients in Jordan.约旦前列腺癌患者中某基因的新型突变
Curr Issues Mol Biol. 2024 Sep 4;46(9):9856-9866. doi: 10.3390/cimb46090586.
J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6.
4
Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans.鉴定非洲裔美国人中已知前列腺癌易感基因座的遗传风险。
PLoS Genet. 2011 May;7(5):e1001387. doi: 10.1371/journal.pgen.1001387. Epub 2011 May 26.
5
Identification of a cell of origin for human prostate cancer.鉴定人类前列腺癌的起源细胞。
Science. 2010 Jul 30;329(5991):568-71. doi: 10.1126/science.1189992.
6
A luminal epithelial stem cell that is a cell of origin for prostate cancer.一种作为前列腺癌起源细胞的管腔上皮干细胞。
Nature. 2009 Sep 24;461(7263):495-500. doi: 10.1038/nature08361. Epub 2009 Sep 9.
7
Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk.Toll样受体基因簇(TLR10-TLR1-TLR6)中的基因变异与前列腺癌风险
Int J Cancer. 2008 Dec 1;123(11):2644-50. doi: 10.1002/ijc.23826.
8
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer.2p15和Xp11.22上的常见序列变异赋予前列腺癌易感性。
Nat Genet. 2008 Mar;40(3):281-3. doi: 10.1038/ng.89. Epub 2008 Feb 10.
9
Multiple newly identified loci associated with prostate cancer susceptibility.多个新发现的与前列腺癌易感性相关的基因座。
Nat Genet. 2008 Mar;40(3):316-21. doi: 10.1038/ng.90. Epub 2008 Feb 10.
10
Cumulative association of five genetic variants with prostate cancer.五种基因变异与前列腺癌的累积关联。
N Engl J Med. 2008 Feb 28;358(9):910-9. doi: 10.1056/NEJMoa075819. Epub 2008 Jan 16.